New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
09:03 EDTONXX, BAYRYBayer and Onyx Pharmaceuticals say sorafenib trial did not meet primary endpoint
Bayer (BAYRY) and Onyx Pharmaceuticals (ONXX) said a Phase III Trial of sorafenib, an adjuvant therapy for a form of liver cancer, did not meet primary endpoint. "We are disappointed that the trial did not meet its primary endpoint. However, we remain committed to exploring the full potential of sorafenib in all stages of liver cancer," said the Bayer HealthCare Executive Committee.
News For BAYRY;ONXX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
12:17 EDTBAYRYBayer, Cardinal Health sign contract manufacturing agreement for Xofigo
Subscribe for More Information
December 16, 2014
08:11 EDTBAYRYFoamix earns $2.5M milestone payment from Bayer
Subscribe for More Information
December 10, 2014
07:56 EDTBAYRYUBS to hold a conference
Agriculture Investor Day is being held in Chicago on December 10.
December 9, 2014
12:22 EDTBAYRYPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
10:23 EDTBAYRYOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:38 EDTBAYRYBayer downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use